For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)\r\n* Hemoglobin >= . g/dl at baseline (may receive red blood cell [RBC] transfusions)
For patients with solid tumors without known bone marrow involvement: \r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)\r\n* Hemoglobin >= . g/dl at baseline (may receive packed red blood cell [PRBC] transfusions)
For patients with solid tumors without known bone marrow involvement: platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)\r\n* Hemoglobin >=  g/dL
Platelet count >= ,/uL (transfusion independent, defined as not receiving platelet transfusions within a  day period prior to enrollment) for patients with solid tumors without bone marrow involvement
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)\r\n* Hemoglobin >= . g/dL at baseline (may receive red blood cell [RBC] transfusions)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^ within  days prior to enrollment \r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For subjects with solid tumors without known bone marrow involvement: platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For subjects with solid tumors without known bone marrow involvement: \r\n*Platelet count ? ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For patients with solid tumors without bone marrow involvement: platelet count >= ,/uL (transfusion independent, defined as not receiving platelet transfusions within a  day period prior to enrollment)
For patients with solid tumors and known bone marrow metastatic disease: platelet count >= ,/uL (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For patients with solid tumors without bone marrow involvement: platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For patients with solid tumors without known bone marrow involvement: platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
For patients with solid tumors or ALCL without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment)
Platelet count >= ,/uL for patients with solid tumors without bone marrow involvement (transfusion independent, defined as not receiving platelet transfusions within a  day period prior to enrollment); platelet count >= ,/uL for patients with known bone metastatic disease (transfusions are permitted to reach the platelet criteria)
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= /mm^\r\n* Platelet count >= ,/mm^ (transfusion independent, defined as not receiving platelet transfusions for at least  days prior to enrollment
